Apalutamide is the first non-metastatic, castration-resistant prostate cancer (NM-CRPC) treatment approved by the FDA.1 The approval is based upon data from the phase III SPARTAN study, which was presented at the 2018 Genitourinary Cancers Symposium and published in the New England Journal of Medici...

Various approaches to managing urinary disorders have been developed in recent years. Different therapies ranging from surgical interventions to pharmacological therapies, as well as catheterization or the endourethral prosthetic devices have become available. At the UAA Congress 2017, Dr. Hann-Chor...